Pricing Debate: GAO Report On Rx Profits Offers Ammunition To Both Sides
Executive Summary
Sen. Sanders and Rep. Cummings requested the study, which notes industry's healthy margins and offers concerns about mergers – but emphasizes the increasing cost of R&D.